News

The FDA has approved cysteamine ophthalmic solution (Cystaran, Sigma-Tau Pharmaceuticals) 0.44% for corneal cystine crystal accumulation in patients with cystinosis.

The FDA has cleared the additional indication of corneal flap creation in refractive surgical procedures for a femtosecond laser platform (LenSx Laser, Alcon).

A video description of Cataract Surgery: Telling It Like It Is!, cataract meeting organized by Robert H. Osher, MD.

To clarify whether total intracranial CSF volume increases in IIH, researchers prospectively studied MRI-derived measures of total cranial, ventricular, and extraventricular CSF volumes in patients with IIH and controls. Results showed that the extraventricular CSF space was significantly greater in the patient group versus the controls. The ventricular volume was the same between the two groups.

Aflibercept (Eylea, Regeneron) has gained FDA approval for treatment of macular edema following CRVO and recommendation for approval by the CHMP for treatment of neovascular AMD.

A phase IIa proof of concept study of a novel rho-kinase (ROCK) inhibitor (AMA0076, Amakem NV) is now underway in patients with glaucoma and ocular hypertension.

QLT Inc. announces that it has completed sale of verteporfin for injection (Visudyne) to Valeant Pharmaceuticals International Inc.

Certain eye movement patterns seem to be associated with better face recognition performance in patients with central glaucomatous visual field loss.

A scientific research grant to cover studies related to dry eye and ocular surface disease will be awarded by CLAO ERF in association with the SSF.

The FDA has granted additional labeling indications for besifloxacin ophthalmic suspension 0.6% (Besivance, Bausch + Lomb).

A study provides new insight on the risk of early ocular surface-related complications among patients undergoing CXL for keratoconus.

The iDesign aberrometer (Abbott) provides an advanced, high-definition measurement device for wavefront-guided LASIK procedures.

The AcrySof IQ ReSTOR +2.5-D IOL offers sharp distance vision with an additional range of vision beyond a standard monofocal lens.

In today's blog from ESCRS, Mark Dlugoss, Ophthalmology Times editor-in-chief, discusses ophthalmic technologies and FDA-related availability issues.

The company promotes two and adds another employee as it names three vice presidents.

Pseudophakic patients may benefit from a fluocinolone acetonide intravitreal implant (Iluvien, Alimera Sciences), the company tells a United Kingdom committee.

A cellular-level adaptive optics retinal camera (rtx1, Imagine Eyes) has received CE mark approval in the European Union.

A new sealant (ReSure, Ocular Therapeutix) will be studied for clear corneal incision closure after cataract extraction or IOL placement.

Improved efficacy and dosing convenience are the aims of a new drug delivery system incorporating a cationic polymer and formulated with ketorolac.

New data presented at the European Society of Retina Specialists meeting suggest that ranibizumab is effective in patients with AMD, DME, and RVO.

Newly published research gives ophthalmologists a reason to encourage their adult patients with visual field loss in both eyes to be more physically active.

Mark Dlugoss, Ophthalmology Times editor-in-chief, is blogging daily from ESCRS. Today he discusses the attendance of Latin American physicians at ESCRS.

Ophthalmology Times editor-in-chief, Mark Dlugoss, is blogging daily from ESCRS. Today he discusses various releases of intraocular lenses (IOLs).

Ophthalmology Times Editor-in-Chief, Mark Dlugoss, blogs daily from the 2012 congress of the European Society of Cataract and Refractive Surgeons (ESCRS).

Researchers have identified the mode of death of cone photoreceptor cells in an animal model of retinitis pigments (RP).

Glaucoma and age-related macular degeneration (AMD) research grants have been awarded to Wilmer Eye Institute by the American Health Assistance Foundation.

The Welch Allyn facility in Beaverton, OR, earned Leadership in Energy and Environmental Design (LEED) certification from the U.S. Green Building Council.

William M. Moore has been named interim president and chief executive officer of Iridex Corp. Moore succeeds Dominik Beck.